Revolutionizing Antibody Discovery with AI-Inspired Design

For decades, researchers and biopharma scientists have relied upon conventional tools, such as biolayer interferometry (BLI) mouse antibody HIS-tag capture probes, to drive antibody discovery. However, the fundamental challenges of this traditional approach often limit the utility of conventional BLI binding probes for broader, more sensitive applications.


The Core Challenges of Traditional His-Tag Screening:

  • Baseline drift that skews long-term kinetic data.
  • Low signal resolution making weak interactions hard to detect.
  • Poor-quality data when analyzing low-concentration binders.


Introducing the NovoBody™ HIS XT Probe

To solve these persistent bottlenecks, a strategic partnership between GatorBio and Monod Bio has brought to life the innovative NovoBody™ HIS XT probe technology. As the first commercially available BLI probe to incorporate AI-inspired binding protein design, the NovoBody HIS XT delivers superior baseline stability, unmatched signal resolution, and ultra-high specificity.


Validated Applications for Next-Gen Antibody Discovery:

The NovoBody HIS XT serves as a highly effective, robust solution for a wide range of critical His-tag analysis applications, including:

  • Kinetic and equilibrium binding studies
  • Epitope mapping and binning
  • Fc receptor binding assays
  • Phage and yeast display screenings
  • Cell-free screening workflows

Check out our new infographic to learn more.